Precision proteomics at the interface of immunology and oncology
  • Targeted analysis of immuno-oncology biomarkers to gain a better understanding of the interplay between the immune system and tumors, to assess therapeutic efficacy and provide a basis for patient stratification (BiomarkerScout™)
  • System-wide analysis of tumor genomes and proteomes to identify unique immuno-oncology targets for antibody-based therapeutics (KinomeScout™, ProteomeScout™, proteogenomics solutions)
  • Comprehensive study of cell surface proteins, secreted and glycosylated proteins to identify potential immuno-oncology targets, novel potential targets for antibody drug conjugate (ADC) cancer therapy or markers for patient stratification (ProteomeScout™, secretome and glycoproteome analysis)


Further reading

Yu, K.H., and Snyder, M. (2016) Omics Profiling in Precision Oncology, Mol Cell Proteomics 15(8):2525-36. [Link]

Haura, E.B., Beg, A.A., Rix, U., and Antonia, S. (2015) Charting immune signaling proteomes en route to new therapeutic strategies, Cancer Immunol Res 3(7): 714–720. [Link]

Nature Reviews Cancer Web Focus: Cancer Proteomics. [Link]


Lymphocytes attacking a cancer cell
OmicScouts' technologies can be used to study the interplay between the immune system and tumor cells.